DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139,659,620 | +3.5% | 562,917 | +0.1% | 1.80% | +7.3% |
| Q2 2023 | $134,918,196 | +4.5% | 562,159 | +9.8% | 1.67% | -2.3% |
| Q1 2023 | $129,066,129 | -5.7% | 512,086 | -0.6% | 1.71% | -8.2% |
| Q4 2022 | $136,804,897 | +5.3% | 515,428 | +2.4% | 1.87% | -3.1% |
| Q3 2022 | $129,978,000 | +3.0% | 503,224 | +1.1% | 1.93% | +7.6% |
| Q2 2022 | $126,198,000 | +0.9% | 497,785 | +16.9% | 1.79% | +15.5% |
| Q1 2022 | $125,028,000 | -8.1% | 425,875 | +3.0% | 1.55% | -6.9% |
| Q4 2021 | $136,102,000 | +6.0% | 413,408 | -1.9% | 1.66% | -3.1% |
| Q3 2021 | $128,347,000 | +12.3% | 421,294 | -1.0% | 1.72% | +8.7% |
| Q2 2021 | $114,299,000 | +17.1% | 425,581 | -1.7% | 1.58% | +7.8% |
| Q1 2021 | $97,576,000 | +1.2% | 433,112 | -0.2% | 1.47% | -8.7% |
| Q4 2020 | $96,452,000 | +1.4% | 433,842 | -1.7% | 1.61% | -8.8% |
| Q3 2020 | $95,148,000 | +18.2% | 441,498 | -2.9% | 1.76% | +8.4% |
| Q2 2020 | $80,472,000 | +27.0% | 454,618 | -0.6% | 1.63% | +16.0% |
| Q1 2020 | $63,361,000 | -12.3% | 457,176 | -2.8% | 1.40% | +3.0% |
| Q4 2019 | $72,279,000 | +5.0% | 470,415 | -1.2% | 1.36% | -0.7% |
| Q3 2019 | $68,852,000 | -0.8% | 476,156 | -1.9% | 1.37% | -4.5% |
| Q2 2019 | $69,387,000 | +2.0% | 485,499 | -5.8% | 1.44% | -1.2% |
| Q1 2019 | $68,037,000 | +24.6% | 515,356 | -2.7% | 1.45% | +9.4% |
| Q4 2018 | $54,590,000 | -6.8% | 529,390 | -1.8% | 1.33% | +2.1% |
| Q3 2018 | $58,565,000 | +9.6% | 538,978 | -0.5% | 1.30% | -0.7% |
| Q2 2018 | $53,454,000 | -3.4% | 541,700 | -4.1% | 1.31% | -7.4% |
| Q1 2018 | $55,328,000 | -2.0% | 565,096 | -7.1% | 1.42% | +0.4% |
| Q4 2017 | $56,466,000 | +8.5% | 608,346 | +0.2% | 1.41% | +2.5% |
| Q3 2017 | $52,054,000 | +5.9% | 606,841 | +4.2% | 1.38% | +0.5% |
| Q2 2017 | $49,153,000 | +4.9% | 582,455 | +6.3% | 1.37% | +1.0% |
| Q1 2017 | $46,869,000 | +12.6% | 547,991 | +2.4% | 1.36% | +5.8% |
| Q4 2016 | $41,642,000 | +4.1% | 534,970 | +4.8% | 1.28% | +0.1% |
| Q3 2016 | $40,000,000 | -8.4% | 510,277 | +18.0% | 1.28% | -11.0% |
| Q2 2016 | $43,684,000 | +2.1% | 432,516 | -4.1% | 1.44% | -4.0% |
| Q1 2016 | $42,793,000 | +2.2% | 451,126 | +0.0% | 1.50% | +2.0% |
| Q4 2015 | $41,890,000 | +5.2% | 451,017 | -3.5% | 1.47% | +0.4% |
| Q3 2015 | $39,830,000 | -14.9% | 467,445 | -14.5% | 1.46% | -7.0% |
| Q2 2015 | $46,805,000 | +0.5% | 546,852 | -0.3% | 1.57% | +0.7% |
| Q1 2015 | $46,549,000 | -1.8% | 548,292 | -0.9% | 1.56% | +0.1% |
| Q4 2014 | $47,422,000 | +13.1% | 553,291 | +0.2% | 1.56% | +11.0% |
| Q3 2014 | $41,944,000 | +4.6% | 552,046 | +8.4% | 1.40% | -1.9% |
| Q2 2014 | $40,091,000 | +9.9% | 509,226 | +4.7% | 1.43% | +6.9% |
| Q1 2014 | $36,486,000 | +4.4% | 486,484 | +7.4% | 1.34% | +3.8% |
| Q4 2013 | $34,959,000 | +18.1% | 452,841 | +6.0% | 1.29% | +9.3% |
| Q3 2013 | $29,604,000 | +44.3% | 427,073 | +31.8% | 1.18% | +38.7% |
| Q2 2013 | $20,517,000 | – | 324,131 | – | 0.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |